Clinical Trial Update: A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) [Phase 1, Phase 2]

View source ↗

Summary

A multicentre, open-label Phase 1/2 trial is evaluating frontline regimens R-CHOP/Pola-RCHP and Glofitamab in younger patients with high-risk Diffuse Large B-Ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Glofitamab (glofitamab)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING